Federal Register / Vol. 87, No. 93 / Friday, May 13, 2022 / Notices 29383 

TechEn, Inc., Milford, MA; Technion 

Research and Development Foundation 

Ltd, Haifa, ISR; TetraCells, Inc., 

Marietta, GA; The University of Texas at 

Tyler, Tyler, TX; TrainXR LLC, Las 

Vegas, NV; University of Oregon, 

Eugene, OR; University of Texas 

Medical Branch at Galveston, Galveston, 

TX; University of Texas Permian Basin, 

Odessa, TX; University of Texas System, 

Austin, TX; Valtamer Oy, Helsinki, FIN; 

Vista LifeSciences, Inc. dba Vista 

Partners, Parker, CO; Vistendo, Inc., 

Arcadia, CA; War Horses for Veterans, 

Inc., Stilwell, KS; Wave Neuroscience, 

Inc., Newport Beach, CA; and Xomix 

Ltd, Chicago, IL, been added as parties 

to this venture. 

Also, Advancement Strategy LLC, 

Columbia, MD; Aktiv Pharma Group, 

Broomfield, CO; Alcamena Stem Cell 

Therapeutics LLC, Halethorpe, MD; 

Aldyn, Inc., Boston, MA; American 

Systems, Chantilly, VA; Arcos, Inc., 

Missouri City, TX; ARD Global LLC, 

McLean, VA; Avera Health, Sioux Falls, 

SD; Belle Artificial Intelligence 

Corporation, Cambridge, MA; Brainbox 

Solutions, Inc., Richmond, VA; Canvas 

Incorporated, Huntsville, AL; Capricor 

Therapeutics, Inc., Beverly Hills, CA; 

Carahsoft Technology Corporation, 

Reston, VA; Catharsis Productions, 

Chicago, IL; Cimarron Software 

Services, Inc., Houston, TX; Circadian 

Positioning Systems, Inc., Newport, RI; 

Cognosante, Falls Church, VA; 

Computer Technology Associates, Inc., 

Ridgecrest, CA; Dascena, Houston, TX; 

Delta Chase LLC, West Chester, OH; 

Dovel Technologies, McLean, VA; 

Dustoff Technologies LLC, Saint 

Augustine, FL; Exciton Technologies, 

Inc., Edmonton, Alberta, CAN; 

Expesicor, Inc., Missoula, MT; 

Exploration Institute, Cheyenne, WY; 

FesariusTherapeutics, Inc., Brooklyn, 

NY; Florida International University 

Board of Trustees, Miami, FL; FUJIFILM 

Pharmaceuticals USA, Inc., Valhalla, 

NY; GEN–AVIV LLC, North Miami 

Beach, FL; Georgia State University 

Research Foundation, Inc., Atlanta, GA; 

GreyScan, Inc., Melbourne, AUS; iGov 

Technologies, Inc., Tampa, FL; Kurve 

Technology, Inc., Lynnwood, WA; Luna 

Innovations Incorporated, Roanoke, VA; 

Martellus Pty, Ltd., Sydney, AUS; 

Maryland Development Center, 

Baltimore, MD; Navitas Business 

Consulting, Inc., Herndon, VA; Odyssey 

Systems Consulting Group, Ltd., 

Wakefield, MA; Opticyte, Inc., Seattle, 

WA; Parallax Advanced Research 

Corporation, Beavercreek, OH; Parnell 

Pharmaceuticals, Inc., San Rafael, CA; 

Pennsylvania State University, 

University Park, PA; PhAST Corp., 

Cambridge, MA; Phiex Technologies, 

Inc., Boston, MA; Plantiga Technologies, 

Inc., Vancouver, CAN; PreVeteran 

Group LLC, Jackson, WY; Rain 

Technologies LLC, Las Vegas, NV; 

Research Bridge Partners, Inc., Austin, 

TX; Retia Medical LLC, Valhalla, NY; 

Rhode Island Hospital, Providence, RI; 

RIVA Solutions, Inc., Mclean, VA; 

Rockland Technimed Limited, Mahwah, 

NJ; San Diego State University, San 

Diego, CA; SanMelix Laboratories, Inc., 

Hollywood, FL; Sentio Solutions, Inc., 

San Francisco, CA; Seventh Dimension 

LLC, Mocksville, NC; Sibel, Inc., 

Evanston, IL; SweetBio, Inc., Memphis, 

TN; Tagup, Inc., Somerville, MA; ThinkDragon LLC, Ellicott City, MD; Thornton 

Tomasetti, Inc., New York, NY; Throne 

Biotechnologies, Inc., Paramus, NJ; 

TITUS Sports Academy LLC, 

Tallahassee, FL; Turner Innovations, 

Orem, UT; University of New 

Hampshire, Durham, NH; VES LLC, 

Wilmington, OH; Virginia 

Commonwealth University, Richmond, 

VA; W.R. Joyce Incorporated, Michigan 

City, IN; ZIEN Medical Technologies, 

Inc., Salt Lake City, UT, has withdrawn 

as parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and MTEC 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On May 9, 2014, MTEC filed its 

original notification pursuant to Section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to Section 6(b) of the 

Act on June 9, 2014 (79 FR 32999). 

The last notification was filed with 

the Department on February 4, 2022. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on March 11, 2022 (87 FR 14041). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2022–10244 Filed 5–12–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Medical CBRN Defense 

Consortium 

Notice is hereby given that, on April 

7, 2022, pursuant to Section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), Medical CBRN 

Defense Consortium (‘‘MCDC’’) has filed 

written notifications simultaneously 

with the Attorney General and the 

Federal Trade Commission disclosing 

changes in its membership. The 

notifications were filed for the purpose 

of extending the Act’s provisions 

limiting the recovery of antitrust 

plaintiffs to actual damages under 

specified circumstances. 

Specifically, 7 Hills Pharma LLC, 

Houston, TX; Aleph Therapeutics, Inc., 

Stanford, CA; Amaratek, San Diego, CA; 

Applied Research Associates, Inc.; 

Albuquerque, NM; Horizons Global 

Solutions LLC; Purcellville, VA; Icahn 

School of Medicine at Mount Sinai; 

New York, NY; Iowa State University of 

Science and Technology; Ames, IA; 

Mainstream Engineering Corporation; 

Rockledge, FL; Najit Technologies, Inc.; 

Beaverton, OR; National Strategic 

Research Institute; Lincoln, NE; POP 

Biotechnologies, Inc.; Buffalo, NY; The 

Henry M. Jackson Foundation for the 

Advancement of Military Medicine; 

Bethesda, MD; University of 

Massachusetts; Lowell, MA and Virion 

Therapeutics LLC; Newark, DE have 

been added as parties to this venture. 

Also, Aardvark Medical, Inc., Ross, 

CA; Cytonus Therapeutics, Inc., 

Columbus, OH; Entasis Therapeutics, 

Waltham, MA; EUSA Pharma (US) LLC, 

Burlington, MA; GeneCapture, Inc., 

Huntsville, AL; and Visby Medical, Inc., 

San Jose, CA, have withdrawn as parties 

to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and MCDC 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On November 13, 2015, MCDC filed 

its original notification pursuant to 

Section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to Section 

6(b) of the Act on January 6, 2016 (81 

FR 513). 

The last notification was filed with 

the Department on January 10, 2022. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on March 10, 2022 (87 FR 13756). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2022–10239 Filed 5–12–22; 8:45 am] 

BILLING CODE P 


lotter on DSK11XQN23PROD with NOTICES1